Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions-Reference-Cited by-同舟云学术

Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions

Published:2024-04 Issue: Volume:196 Page:104324
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Gerosa Riccardo,De Sanctis Rita^ORCID,Jacobs Flavia,Benvenuti Chiara,Gaudio Mariangela,Saltalamacchia Giuseppe,Torrisi Rosalba,Masci Giovanna,Miggiano Chiara,Agustoni Francesco,Pedrazzoli Paolo,Santoro Armando,Zambelli Alberto

Publisher

Elsevier BV

Reference46 articles.

1. Emerging therapeutics for patients with triple-negative breast cancer;Agostinetto;Curr. Oncol. Rep.,2021

2. Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer;Al-Qasem;NPJ Precis Oncol.,2022

3. Alpelisib for PIK3CA -mutated, hormone receptor–positive advanced breast cancer;André;N. Engl. J. Med.,2019

4. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity;Arora;Cell,2023

5. Sacituzumab govitecan in metastatic triple-negative breast cancer;Bardia;N. Engl. J. Med.,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancement in developing small molecular inhibitors targeting key kinase pathways against triple-negative breast cancer;Bioorganic & Medicinal Chemistry;2024-10

2. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer;Current Pharmaceutical Biotechnology;2024-07-31

3. Identification of the potential Pan-CDK antagonists: tracing the path of virtual screening and inhibitory activity on lung cancer cells;Molecular Diversity;2024-07-29

4. Inhibitors and PROTACs of CDK2: challenges and opportunities;Expert Opinion on Drug Discovery;2024-07-12

5. Toward Precision Oncology: The Role of TPD in Targeting CDK2 and Beyond;ACS Medicinal Chemistry Letters;2024-06-24